Report produced on 10 September 2026 · data as of the dates shown per section Sources: official issuer documents (KID, factsheet, declared NAV series and holdings), ESMA register, ECB rates, Eurostat Public methodology: rebalix.com/en/methodology
Informational document generated by rebalix.com — facts side by side, no recommendations. It does not constitute investment advice or investment research under Directive 2014/65/EU (MiFID II). Past performance is not indicative of future results.
HCAM — iShares $ EM Bond UCITS ETF · IE000IGHAU32 · Bonds · Government USD · Broad (all maturities) · Emerging markets
HCEM — iShares $ EM Bond UCITS ETF · IE0007WEUBZ2 · Bonds · Government USD · Broad (all maturities) · Emerging markets
Geographic composition
% of portfolio, from full declared holdings
Sector composition
GICS sectors, same sources and dates
Portfolio overlap
101 common holdings · ticker match on full official portfolios
How the shared part is computed: for each security held by both funds, only the SMALLER of the two weights counts — a stock at 5% in one fund and 1% in the other overlaps by 1%, not 5%. Summed over all 101 common holdings this gives 99.9%: buying both funds, roughly this share of your money buys the same stocks twice.
Indicative cumulative cost: on 10,000 euro over 5 years (stated assumption: 5%/yr growth, cost = TER + transaction) ~203 euro HCAM · ~203 euro HCEM. Broker costs not included.
Disclaimer
This document is for information only and does not constitute investment advice under Directive 2014/65/EU (MiFID II), investment research, a personal recommendation, or an offer or solicitation to buy or sell financial instruments.
Past performance is not indicative of, nor a guarantee of, future results. The value of an investment can go down as well as up and investors may not get back the capital invested. Euro returns are affected by currency fluctuations.
Before any investment decision, read the KID and the Prospectus, available from the issuers. Tax treatment depends on individual circumstances and may change.
Data come from official issuer documents and public registers, following the public methodology at rebalix.com/en/methodology. "—" fields were not published by the source and have not been estimated. Rebalix receives no compensation from the issuers mentioned.